Aflibercept

(Eylea®)

Aflibercept

Drug updated on 11/8/2023

Dosage FormInjection (intravitreal; 2 mg/0.05 mL)
Drug ClassVascular endothelial growth factor (VEGF) inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of neovascular (wet) age-related macular degeneration (AMD).
  • For the treatment of macular edema following retinal vein occlusion (RVO).
  • For the treatment of diabetic macular edema (DME).
  • For the treatment of diabetic retinopathy (DR).
  • For the treatment of Retinopathy of Prematurity (ROP).

Product Monograph / Prescribing Information

Document TitleYearSource
Eylea (aflibercept) Prescribing Information.2023Regeneron Pharmaceuticals, Inc., Tarrytown, NY

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Assessment report variation: Eylea.2023EMA
Efficacy and safety of anti-vascular endothelial growth agents for the treatment of polypoidal choroidal vasculopathy: a systematic review and meta-analysis.2023Survey of Ophthalmology
Efficacy and safety of brolucizumab, aflibercept, and ranibizumab for the treatment of patients with visual impairment due to diabetic macular oedema: a systematic review and network meta-analysis.2023Diabetes Therapy
Aflibercept for long-term treatment of diabetic macular edema and proliferative diabetic retinopathy: a meta-analysis.2023Frontiers in Endocrinology
Treat and extend regimen for diabetic macular oedema-a systematic review and meta-analysis.2023Graefe's Archive for Clinical and Experimental Ophthalmology
The efficacy and ocular safety following aflibercept, conbercept, ranibizumab, bevacizumab, and laser for retinopathy of prematurity: a systematic review and meta-analysis.2023Italian Journal of Pediatrics
Determining the Superiority of Vitrectomy vs Aflibercept for Treating Dense Diabetic Vitreous Hemorrhage: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.2023Clinical Ophtalmology
Role of anti-vascular endothelial growth factor in the management of non-proliferative diabetic retinopathy without centre-involving diabetic macular oedema: a meta-analysis of trials.2023Eye
Effect of anti-VEGF therapy on the disease progression of neovascular age-related macular degeneration: a systematic review and model-based meta-analysis.2022The Journal of Clinical Pharmacology
Comparative effectiveness of intravitreal anti-vascular endothelial growth factor therapies for managing neovascular age-related macular degeneration: a meta-analysis.2022Journal of Clinical Medicine
The 12- and 24-month effects of intravitreal ranibizumab, aflibercept, and bevacizumab on intraocular pressure: a network meta-analysis.2022Ophthalmology
Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy.2022BMC Health Services Research
Comparison of intravitreal aflibercept and dexamethasone implant in the treatment of macular edema associated with diabetic retinopathy or retinal vein occlusion: a meta-analysis and systematic review.2022International Journal of Ophthalmology
Efficacy and safety of aflibercept therapy for diabetic macular edema: a systematic review and meta-analysis.2022Journal of Current Ophthalmology
Comparative efficacy of brolucizumab in the treatment of neovascular age-related macular degeneration: a systematic literature review and network meta-analysis.2022Advances in Therapy
Real-World Evidence in the Management of Diabetic Macular Edema with Intravitreal Anti-VEGFs in Asia: A Systematic Literature Review.2022Clinical Ophthalmology
Pro re nata versus fixed aflibercept regimen for neovascular age-related macular degeneration: a systematic review and meta-analysis.2022International Journal of Retina and Vitreous
Different Anti-Vascular Endothelial Growth Factor for Patients With Diabetic Macular Edema: A Network Meta-Analysis.2022Frontiers in Pharmacology
Association Between Visual Acuity and Residual Retinal Fluid Following Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-analysis.2022JAMA Ophtalmology
Safety and Outcomes of Intravitreal Aflibercept in Diabetic Macular Edema - A Systematic Review.2022Current Pharmaceutical Design
Managing Neovascular Age-Related Macular Degeneration in Clinical Practice: Systematic Review, Meta-Analysis, and Meta-Regression.2022Journal of Clinical medicine
Relationship Between Macular Thickness and Visual Acuity in the Treatment of Diabetic Macular Edema With Anti-VEGF Therapy: Systematic Review.2022Journal of Vitreoretinal Diseases
Efficacy and safety of anti–vascular endothelial growth factor monotherapies for neovascular age-related macular degeneration: a mixed treatment comparison. 2021Frontiers in Pharmacology
Anti-vascular endothelial growth factor therapy for age-related macular degeneration: a systematic review and meta-analysis.2021Systematic Reviews
Managing diabetic macular edema in clinical practice: systematic review and meta-analysis of current strategies and treatment options.2021Clinical Ophthalmology
Aflibercept for Retinopathy of Prematurity: A Systematic Review and Meta-Analysis.2021Ophthalmic Surgery, Lasers and Imaging Retina
Real-world effectiveness and real-world cost-effectiveness of intravitreal aflibercept and intravitreal ranibizumab in neovascular age-related macular degeneration: systematic review and meta-analysis of real-world studies.2020Advances in Therapy
Efficacy and treatment burden of intravitreal aflibercept versus intravitreal ranibizumab treat-and-extend regimens at 2 years: network meta-analysis incorporating individual patient data meta-regression and matching-adjusted indirect comparison.2020Advances in Therapy
Efficacy of switching therapy to aflibercept for patients with persistent diabetic macular edema: a systematic review and meta-analysis.2020Annals of Translational Medicine
Comparative safety of bevacizumab, ranibizumab, and aflibercept for treatment of neovascular age-related macular degeneration (AMD): a systematic review and network meta-analysis of direct comparative studies.2020Journal of Clinical Medicine
Comparative efficacy and safety of anti-vascular endothelial growth factor regimens for neovascular age-related macular degeneration: systematic review and Bayesian network meta-analysis.2020Therapeutic Advances in Chronic Disease
Efficacy of conversion to aflibercept for diabetic macular edema previously refractory to bevacizumab or ranibizumab: a meta-analysis of high-quality nonrandomized studies.2020The Annals of Pharmacotherapy
Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.2020The Cochrane Database of Systematic Reviews
Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.2020The Cochrane Database of Systematic Reviews
A meta‐analysis of patients with treatment‐resistant macular oedema secondary to retinal vein occlusions following switching to aflibercept.2019Acta Ophthalmologica
One year effectiveness study of intravitreal aflibercept in neovascular age-related macular degeneration: a meta-analysis.2019Acta Ophthalmologica
Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis.2019BMJ Open
Comparative effectiveness and harms of intravitreal antivascular endothelial growth factor agents for three retinal conditions: a systematic review and meta-analysis.2019The British Journal of Ophthalmology
Comparative efficacy of bevacizumab, ranibizumab, and aflibercept for treatment of macular edema secondary to retinal vein occlusion: a systematic review and network meta-analysis.2018Expert Review of Clinical Pharmacology
The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration-A cost-effectiveness analysis from a societal perspective.2018PLoS One
Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.2018Cochrane Database of Systematic Reviews

Clinical Practice Guidelines